Mineral AbsorptionNCT00868738
Evaluation of Calcium, Vitamin D, Magnesium, and Zinc Absorption in Children
A study testing Vitamin D in people with Mineral Absorption, run by Baylor College of Medicine at 1 site in United States.
Trial summary
The goal of our research is to provide data to enhance the development of nutritional guidelines, especially as related to mineral nutrition, in children. Using human experimentation, we are studying methods of delivering the key minerals of calcium, zinc and iron in the diet so as to optimize health outcomes. Read more about this study
- Who is it for?
- Ages 4 to 8 yearsHealthy volunteers can take part
- Conditions the study is for
- Mineral Absorption
- What is being tested?
- Vitamin D
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteUnited States
- Study dates
- Mar 2009to Oct 2011
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 4 to 8 years
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- Delivery at > or = 35.0 weeks gestation with birth weight > or = 2.5 kg
- BMI: 10th - 90th percentile for age and gender
- Ages 4.0 to 8.9 years
- Ethnic distribution of greater Houston area
- Usual calcium intake 600-1200 mg/d based on two 24-hour dietary recalls by phone
- Any regularly taken (daily) vitamins and minerals must be stopped at least 1 month before starting the study
Who cannot join
- History of any chronic illness.
- Regularly taken (daily) medications (except seasonal allergies).
- Avoidance of dairy products or meat in the diet.
Trial locations and contacts
1 site in 1 country.
United States1 site
Baylor College of Medicine / Texas Children's Hospital
Houston, Texas, 77030
About this study
Official title: Evaluation of Calcium, Vitamin D, Magnesium, and Zinc Absorption in Healthy Children 4 to 8 Years of Age
The goal of our research is to provide data to enhance the development of nutritional guidelines, especially as related to mineral nutrition, in children. Using human experimentation, we are studying methods of delivering the key minerals of calcium, zinc and iron in the diet so as to optimize health outcomes. We will conduct a controlled trial of vitamin D supplementation to assess the effects of vitamin D status on calcium absorption in small children. We will evaluate the effects of differing intakes of zinc on zinc and copper absorption. These studies will utilize stable isotope techniques so as to provide accurate, practically applicable information which may be obtained from the study populations in a safe manner. These data will have global application and provide a strong basis for evidence-based nutritional recommendations to be developed.
Objective #1: To evaluate the effects of supplemental vitamin D in enhancing calcium absorption in healthy children 4 to 8 yrs of age.
Objective #2: Assess the absorption of magnesium and zinc in healthy children 4 to 8 yrs of age.
Read the detailed description
We plan to stratify subjects for randomization to either vitamin D supplements or placebo by serum 25-hydroxyvitamin D (25 OHD) into three groups: 0-20 ng/mL, 20-32 ng/mL, and >32 ng/mL.
There is no group assignment or randomization for the magnesium and zinc aspects of the study.
SCREENING VISIT: At the time of enrollment, subjects and their families will be asked to come to the General Clinical Research Center (GCRC) of Texas Children's Hospital for a screening visit. Prior to this visit, demographics from the parent/guardian will be recorded including the child's approximate height and weight, and the study dietitian will obtain two 24-hour dietary recalls from the parent to determine calcium intake for enrollment. During this screening visit, informed written consent will be obtained, a medical history taken, and a physical examination performed.
The study dietitian will instruct the parent/guardian and child on the use of a food scale to weigh and record dietary intake for a 3-day period (ie, 3-day weighed diet record). The 3-day weighed diet record will begin the following day. This method has been shown to provide the best estimate of dietary intakes in children (Crawford PB et al, J Am Diet Assoc. 1994; 94:626-630; Fisher JO et al, Am J Clin Nutr. 2008; 88:407-415). Upon analysis of their child's intake, parents will be instructed to maintain a similar nutrient intake throughout the study. Compliance will be monitored via 3-day weighed home diet records timed with their other study visits. If analysis shows that the child's intake has significantly changed (± 20% of a nutrient), the parent will be counseled by the study dietitian on readjusting the child's intake back to the usual level determined at baseline.
In addition, the study dietitian will prepare sample menus based on the child's food preferences and dietary intake levels and provide them to the parent. Parents can use the sample menus to assist them in maintaining the child's usual mineral intake.
STUDY VISIT 1: Subjects and a parent/guardian will return to the GCRC for a 24-hour overnight stay, arriving in the morning for a baseline stable isotope study. We will utilize the dual-tracer stable isotope technique as in our previous studies. At this visit subjects will receive intravenous isotope doses 1 mg 42Ca, 6 mg 25Mg, and 0.4 mg 70Zn. At the time of the IV isotope, we will collect a blood sample (10mL for serum calcium, phosphorus, alkaline phosphatase, magnesium, 25OHD, 1,25-dihydroxyvitamin D, hepcidin, ferritin, TIBC, transferrin saturation, hemoglobin, hematocrit, and RBC indices). Topical numbing cream or spray to minimize pain at the injection site will be offered to all subjects.
A dual-energy x-ray absorptiometry (DEXA) measurement of total body bone mineral content/density and body fat will be made. This is done to use as a covariate in evaluating vitamin D levels and calcium absorption.
A 24-hr urine collection while they stay inpatient will begin with the timing of the first isotope. After they are discharged, subjects will be instructed on collecting another 48-hr urine collection (72-hr total) at home as well as a final spot urine at 96 hours after the first isotope.
Subjects will receive oral isotopes (20 mcg 46Ca, 12 mg 26Mg, and 2 mg 67Zn) mixed with 120 mL of calcium and vitamin D-fortified orange juice or milk. The breakfast will be a fixed meal providing a total of ~300 mg calcium. Lunch will provide ~300mg calcium; dinner will provide ~300mg calcium (totaling ~900mg calcium). All meals at the GCRC will be pre- and post-weighed to determine actual intake. After discharge, subjects will record dietary intake using another 3-day weighed diet record.
Approximately one week after Study Visit 1, the results from the serum 25OHD test will be back and we will stratify subjects accordingly into three groups: 0-20 ng/mL, 20-32 ng/mL, and >32 ng/mL. Subjects will return to the CNRC to be provided supplemental vitamin D3 (1000 IU) or placebo, given once daily (based on the stratification noted above). Vitamin D/placebo will be provided using a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks. They will be provided with study calendars to mark daily when they remember to take the supplement. Calendars and remaining supplements will be returned to the study center for counting to determine compliance.
Subjects will return urine samples, food scales, and diet records to the study personnel at the CNRC. The CNRC driver may also be utilized for the purpose of picking up samples or delivering the supplement. Periodic phone calls will be made to the home of the subject to monitor compliance with taking the supplement.
STUDY VISIT 2: Eight (8) weeks after the subjects began taking their supplement, subjects will return to the GCRC for a repeat study of absorption. Prior to this visit, subjects will receive a food scale and will perform another 3-day weighed diet record to demonstrate consistency of diet throughout the study period. Subjects will again arrive in the morning to the GCRC for a 24-hr inpatient study visit. They will bring with them all study calendars and remaining supplements for compliance monitoring. Study Visit 2 is similar in all aspects of Study Visit 1 regarding the calcium and vitamin D portion of the study. Magnesium and zinc measurements will not be repeated at Study Visit 2.
At this visit subjects will receive an intravenous isotope dose of 1 mg 42Ca. At the time of the IV isotope, we will collect a blood sample (same labs as in Study Visit 1). Topical numbing cream or spray to minimize pain at the injection site will be offered to all subjects.
A 24-hr urine collection while they stay inpatient will begin with the timing of the first isotope. After they are discharged, subjects will not be required to continue any additional urine collections.
Subjects will receive 20 mcg 46Ca stable isotope mixed with 120 mL of calcium and vitamin D-fortified orange juice or milk. The breakfast will be a fixed meal providing a total of ~300 mg calcium. Lunch will provide ~300mg calcium; dinner will provide ~300mg calcium (totaling ~900mg calcium). All meals at the GCRC will be pre- and post-weighed to determine actual intake.
Upon discharge, subjects will discontinue the supplementation and the study will be complete.
In interpreting the results, we will note ethnicity, the season of measurement and qualitative descriptions of sun exposure by considering the amount of time spent outside. However, we will not specifically assess sun exposure as this is not practical in small children. In general, we would not expect large changes in these in Houston during the 8 weeks of the study, but will ensure that the two studies do not cross a period of major change such as having the first study done before summer camp and the second right afterwards.
Urine and serum samples will be prepared for mass spectrometric analysis using an oxalate precipitation technique. Samples will be analyzed for isotopic enrichment using a magnetic sector ICP-MS. This is a high-speed instrument capable of analysis of the desired ratio with precision and accuracy of 0.3-0.5%.
Contingencies: We do not anticipate any problems with this study that would require changing or altering the protocol. Our sample size does not allow us to evaluate gender or ethnicity separately to determine differences in effects among these. There is no reason to expect differences in vitamin D effects on calcium absorption based on these (Weaver, personal communication). Additionally, dietary recommendations reflect the diversity of our population and if we identify trends towards specific ethnic or gender effects we can study this further in future population studies. This study will look at absorption only as an endpoint. If a benefit is found, we will develop a long-term trial evaluating bone mineral outcomes. However, this would require larger groups and a full year of study and is beyond the scope of this initial study. If no difference in calcium absorption is shown with 1000 IU/d of vitamin D, it is extremely unlikely that an effect on bone mineral would be found justifying a long-term study.
Magnesium absorption studies require a full 72-hour urine collection for accuracy. It is not practical to keep children this age in-patient for this time so after 24 hours, collections will be done at home. We have extensive experience with assisting families in home urine collections. There is the possibility of some loss of urine in a 72-hour collection. However, in that case we would continue the collection as the method's accuracy is not highly sensitive to the loss of a single or a small number of urine specimens in small children. Magnesium balance is not regulated by endogenous excretion (similar to calcium) and thus the absorption studies will provide adequate information to estimate net balance.
Subjects may be told their weight and height measurements at each visit to the GCRC. All other study related information will be held until the end of the study.
- Conditions
- Mineral Absorption
- Being tested
- Vitamin D
- Keywords
- Calcium, Vitamin D, Magnesium, Zinc
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Vitamin DDietary supplement
Subjects will be provided supplemental vitamin D3 (1000 IU) or placebo, given once daily (based on the stratification noted above). Vitamin D/placebo will be provided using a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks.
| Study group | Role | What they receive |
|---|---|---|
| Vitamin D | Active comparator | Subjects will be provided supplemental vitamin D3 (1000 IU), given once daily as a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks. Receives: Dietary Supplement: Vitamin D |
| Placebo | Placebo comparator | Subjects will be provided a placebo, given once daily as a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks. Receives: Dietary Supplement: Vitamin D |
What is being measured
The primary outcome is the main question the study is designed to answer.
To evaluate the effects of supplemental vitamin D in enhancing calcium absorption in healthy children 4 to 8 yrs of age.
Measured: End of the study
Secondary outcomes (1)
Assess the absorption of magnesium and zinc in healthy children 4 to 8 yrs of age.
Measured: End of the study
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Mar 2009 (estimated)
- Study startMar 2009
- Primary completionAug 2011
- Study completionOct 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (36)Papers the sponsor has linked to this study.
- Other trials for Mineral AbsorptionStudies of the same condition, open and under way.
- More trials run by Baylor College of MedicineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Baylor College of Medicine
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Steve Abrams, Baylor College of Medicine
- Investigators
- Steve Abrams, MD, Principal investigator, Baylor College of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00868738
- Sponsor's protocol ID
- H-24134
- Other IDs
- 6250-51000-045-00D
- Status last verified
- Nov 2011
- First submitted
- 24 Mar 2009
- Last updated
- 2 Nov 2011
- Results posted
- No
- Data monitoring committee
- No
Publications
Abrams SA, Griffin IJ, Hawthorne KM, Liang L, Gunn SK, Darlington G, Ellis KJ. A combination of prebiotic short- and long-chain inulin-type fructans enhances calcium absorption and bone mineralization in young adolescents. Am J Clin Nutr. 2005 Aug;82(2):471-6. doi: 10.1093/ajcn.82.2.471.
PubMed 16087995Abrams SA, Hawthorne KM, Aliu O, Hicks PD, Chen Z, Griffin IJ. An inulin-type fructan enhances calcium absorption primarily via an effect on colonic absorption in humans. J Nutr. 2007 Oct;137(10):2208-12. doi: 10.1093/jn/137.10.2208.
PubMed 17884999Ames SK, Gorham BM, Abrams SA. Effects of high compared with low calcium intake on calcium absorption and incorporation of iron by red blood cells in small children. Am J Clin Nutr. 1999 Jul;70(1):44-8. doi: 10.1093/ajcn/70.1.44.
PubMed 10393137Beard JL, Dawson H, Pinero DJ. Iron metabolism: a comprehensive review. Nutr Rev. 1996 Oct;54(10):295-317. doi: 10.1111/j.1753-4887.1996.tb03794.x.
PubMed 9063021Bischoff-Ferrari HA, Dietrich T, Orav EJ, Dawson-Hughes B. Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med. 2004 May 1;116(9):634-9. doi: 10.1016/j.amjmed.2003.12.029. No abstract available.
PubMed 15093761Bray MS, Shaw CA, Moore MW, Garcia RA, Zanquetta MM, Durgan DJ, Jeong WJ, Tsai JY, Bugger H, Zhang D, Rohrwasser A, Rennison JH, Dyck JR, Litwin SE, Hardin PE, Chow CW, Chandler MP, Abel ED, Young ME. Disruption of the circadian clock within the cardiomyocyte influences myocardial contractile function, metabolism, and gene expression. Am J Physiol Heart Circ Physiol. 2008 Feb;294(2):H1036-47. doi: 10.1152/ajpheart.01291.2007. Epub 2007 Dec 21.
PubMed 18156197Davidsson L, Ziegler EE, Kastenmayer P, Hurrell RF. Erythrocyte incorporation of iron by infants: iron bioavailability from a low-iron infant formula and an evaluation of the usefulness of correcting erythrocyte incorporation values, using a reference dose or plasma ferritin concentrations. Br J Nutr. 2000 Dec;84(6):847-53.
PubMed 11177201Donovan A, Andrews NC. The molecular regulation of iron metabolism. Hematol J. 2004;5(5):373-80. doi: 10.1038/sj.thj.6200540.
PubMed 15448662Eisenstein RS. Iron regulatory proteins and the molecular control of mammalian iron metabolism. Annu Rev Nutr. 2000;20:627-62. doi: 10.1146/annurev.nutr.20.1.627.
PubMed 10940348Fleet JC, Eksir F, Hance KW, Wood RJ. Vitamin D-inducible calcium transport and gene expression in three Caco-2 cell lines. Am J Physiol Gastrointest Liver Physiol. 2002 Sep;283(3):G618-25. doi: 10.1152/ajpgi.00269.2001.
PubMed 12181175Fleet JC, Wood RJ. Specific 1,25(OH)2D3-mediated regulation of transcellular calcium transport in Caco-2 cells. Am J Physiol. 1999 Apr;276(4):G958-64. doi: 10.1152/ajpgi.1999.276.4.G958.
PubMed 10198340Friend DR. Drug delivery to the small intestine. Curr Gastroenterol Rep. 2004 Oct;6(5):371-6. doi: 10.1007/s11894-004-0052-z.
PubMed 15341712Garcia-Casal MN, Leets I, Layrisse M. Beta-carotene and inhibitors of iron absorption modify iron uptake by Caco-2 cells. J Nutr. 2000 Jan;130(1):5-9. doi: 10.1093/jn/130.1.5.
PubMed 10613757Gordon CM, DePeter KC, Feldman HA, Grace E, Emans SJ. Prevalence of vitamin D deficiency among healthy adolescents. Arch Pediatr Adolesc Med. 2004 Jun;158(6):531-7. doi: 10.1001/archpedi.158.6.531.
PubMed 15184215Griffin IJ, Davila PM, Abrams SA. Non-digestible oligosaccharides and calcium absorption in girls with adequate calcium intakes. Br J Nutr. 2002 May;87 Suppl 2:S187-91. doi: 10.1079/BJNBJN/2002536.
PubMed 12088517
Study at a glance
From the registry record, last updated by the sponsor on 2 Nov 2011. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Calcium, Vitamin D, Magnesium, and Zinc Absorption in Healthy Children 4 to 8 Years of Age
- ClinicalTrials.gov ID
- NCT00868738
- Acronym / sponsor ID
- H-24134
- Conditions
- Mineral Absorption
- Keywords
- Calcium, Vitamin D, Magnesium, Zinc
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Baylor College of MedicineUniversity, hospital or other
- Study start
- Mar 2009
- Primary completion
- Aug 2011 (actual)
- Study completion
- Oct 2011 (actual)
- First posted
- 25 Mar 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of our research is to provide data to enhance the development of nutritional guidelines, especially as related to mineral nutrition, in children. Using human experimentation, we are studying methods of delivering the key minerals of calcium, zinc and iron in the diet so as to optimize health outcomes. We will conduct a controlled trial of vitamin D supplementation to assess the effects of vitamin D status on calcium absorption in small children. We will evaluate the effects of differing intakes of zinc on zinc and copper absorption. These studies will utilize stable isotope techniques so as to provide accurate, practically applicable information which may be obtained from the study populations in a safe manner. These data will have global application and provide a strong basis for evidence-based nutritional recommendations to be developed.
Objective #1: To evaluate the effects of supplemental vitamin D in enhancing calcium absorption in healthy children 4 to 8 yrs of age.
Objective #2: Assess the absorption of magnesium and zinc in healthy children 4 to 8 yrs of age.
Detailed description
We plan to stratify subjects for randomization to either vitamin D supplements or placebo by serum 25-hydroxyvitamin D (25 OHD) into three groups: 0-20 ng/mL, 20-32 ng/mL, and >32 ng/mL.
There is no group assignment or randomization for the magnesium and zinc aspects of the study.
SCREENING VISIT: At the time of enrollment, subjects and their families will be asked to come to the General Clinical Research Center (GCRC) of Texas Children's Hospital for a screening visit. Prior to this visit, demographics from the parent/guardian will be recorded including the child's approximate height and weight, and the study dietitian will obtain two 24-hour dietary recalls from the parent to determine calcium intake for enrollment. During this screening visit, informed written consent will be obtained, a medical history taken, and a physical examination performed.
The study dietitian will instruct the parent/guardian and child on the use of a food scale to weigh and record dietary intake for a 3-day period (ie, 3-day weighed diet record). The 3-day weighed diet record will begin the following day. This method has been shown to provide the best estimate of dietary intakes in children (Crawford PB et al, J Am Diet Assoc. 1994; 94:626-630; Fisher JO et al, Am J Clin Nutr. 2008; 88:407-415). Upon analysis of their child's intake, parents will be instructed to maintain a similar nutrient intake throughout the study. Compliance will be monitored via 3-day weighed home diet records timed with their other study visits. If analysis shows that the child's intake has significantly changed (± 20% of a nutrient), the parent will be counseled by the study dietitian on readjusting the child's intake back to the usual level determined at baseline.
In addition, the study dietitian will prepare sample menus based on the child's food preferences and dietary intake levels and provide them to the parent. Parents can use the sample menus to assist them in maintaining the child's usual mineral intake.
STUDY VISIT 1: Subjects and a parent/guardian will return to the GCRC for a 24-hour overnight stay, arriving in the morning for a baseline stable isotope study. We will utilize the dual-tracer stable isotope technique as in our previous studies. At this visit subjects will receive intravenous isotope doses 1 mg 42Ca, 6 mg 25Mg, and 0.4 mg 70Zn. At the time of the IV isotope, we will collect a blood sample (10mL for serum calcium, phosphorus, alkaline phosphatase, magnesium, 25OHD, 1,25-dihydroxyvitamin D, hepcidin, ferritin, TIBC, transferrin saturation, hemoglobin, hematocrit, and RBC indices). Topical numbing cream or spray to minimize pain at the injection site will be offered to all subjects.
A dual-energy x-ray absorptiometry (DEXA) measurement of total body bone mineral content/density and body fat will be made. This is done to use as a covariate in evaluating vitamin D levels and calcium absorption.
A 24-hr urine collection while they stay inpatient will begin with the timing of the first isotope. After they are discharged, subjects will be instructed on collecting another 48-hr urine collection (72-hr total) at home as well as a final spot urine at 96 hours after the first isotope.
Subjects will receive oral isotopes (20 mcg 46Ca, 12 mg 26Mg, and 2 mg 67Zn) mixed with 120 mL of calcium and vitamin D-fortified orange juice or milk. The breakfast will be a fixed meal providing a total of ~300 mg calcium. Lunch will provide ~300mg calcium; dinner will provide ~300mg calcium (totaling ~900mg calcium). All meals at the GCRC will be pre- and post-weighed to determine actual intake. After discharge, subjects will record dietary intake using another 3-day weighed diet record.
Approximately one week after Study Visit 1, the results from the serum 25OHD test will be back and we will stratify subjects accordingly into three groups: 0-20 ng/mL, 20-32 ng/mL, and >32 ng/mL. Subjects will return to the CNRC to be provided supplemental vitamin D3 (1000 IU) or placebo, given once daily (based on the stratification noted above). Vitamin D/placebo will be provided using a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks. They will be provided with study calendars to mark daily when they remember to take the supplement. Calendars and remaining supplements will be returned to the study center for counting to determine compliance.
Subjects will return urine samples, food scales, and diet records to the study personnel at the CNRC. The CNRC driver may also be utilized for the purpose of picking up samples or delivering the supplement. Periodic phone calls will be made to the home of the subject to monitor compliance with taking the supplement.
STUDY VISIT 2: Eight (8) weeks after the subjects began taking their supplement, subjects will return to the GCRC for a repeat study of absorption. Prior to this visit, subjects will receive a food scale and will perform another 3-day weighed diet record to demonstrate consistency of diet throughout the study period. Subjects will again arrive in the morning to the GCRC for a 24-hr inpatient study visit. They will bring with them all study calendars and remaining supplements for compliance monitoring. Study Visit 2 is similar in all aspects of Study Visit 1 regarding the calcium and vitamin D portion of the study. Magnesium and zinc measurements will not be repeated at Study Visit 2.
At this visit subjects will receive an intravenous isotope dose of 1 mg 42Ca. At the time of the IV isotope, we will collect a blood sample (same labs as in Study Visit 1). Topical numbing cream or spray to minimize pain at the injection site will be offered to all subjects.
A 24-hr urine collection while they stay inpatient will begin with the timing of the first isotope. After they are discharged, subjects will not be required to continue any additional urine collections.
Subjects will receive 20 mcg 46Ca stable isotope mixed with 120 mL of calcium and vitamin D-fortified orange juice or milk. The breakfast will be a fixed meal providing a total of ~300 mg calcium. Lunch will provide ~300mg calcium; dinner will provide ~300mg calcium (totaling ~900mg calcium). All meals at the GCRC will be pre- and post-weighed to determine actual intake.
Upon discharge, subjects will discontinue the supplementation and the study will be complete.
In interpreting the results, we will note ethnicity, the season of measurement and qualitative descriptions of sun exposure by considering the amount of time spent outside. However, we will not specifically assess sun exposure as this is not practical in small children. In general, we would not expect large changes in these in Houston during the 8 weeks of the study, but will ensure that the two studies do not cross a period of major change such as having the first study done before summer camp and the second right afterwards.
Urine and serum samples will be prepared for mass spectrometric analysis using an oxalate precipitation technique. Samples will be analyzed for isotopic enrichment using a magnetic sector ICP-MS. This is a high-speed instrument capable of analysis of the desired ratio with precision and accuracy of 0.3-0.5%.
Contingencies: We do not anticipate any problems with this study that would require changing or altering the protocol. Our sample size does not allow us to evaluate gender or ethnicity separately to determine differences in effects among these. There is no reason to expect differences in vitamin D effects on calcium absorption based on these (Weaver, personal communication). Additionally, dietary recommendations reflect the diversity of our population and if we identify trends towards specific ethnic or gender effects we can study this further in future population studies. This study will look at absorption only as an endpoint. If a benefit is found, we will develop a long-term trial evaluating bone mineral outcomes. However, this would require larger groups and a full year of study and is beyond the scope of this initial study. If no difference in calcium absorption is shown with 1000 IU/d of vitamin D, it is extremely unlikely that an effect on bone mineral would be found justifying a long-term study.
Magnesium absorption studies require a full 72-hour urine collection for accuracy. It is not practical to keep children this age in-patient for this time so after 24 hours, collections will be done at home. We have extensive experience with assisting families in home urine collections. There is the possibility of some loss of urine in a 72-hour collection. However, in that case we would continue the collection as the method's accuracy is not highly sensitive to the loss of a single or a small number of urine specimens in small children. Magnesium balance is not regulated by endogenous excretion (similar to calcium) and thus the absorption studies will provide adequate information to estimate net balance.
Subjects may be told their weight and height measurements at each visit to the GCRC. All other study related information will be held until the end of the study.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Vitamin D | Active comparator | Dietary Supplement: Vitamin DSubjects will be provided supplemental vitamin D3 (1000 IU), given once daily as a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks. |
| Placebo | Placebo comparator | Dietary Supplement: Vitamin DSubjects will be provided a placebo, given once daily as a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks. |
Who may qualify
- Ages
- 4 to 8 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (6 listed)
- Delivery at > or = 35.0 weeks gestation with birth weight > or = 2.5 kg
- BMI: 10th - 90th percentile for age and gender
- Ages 4.0 to 8.9 years
- Ethnic distribution of greater Houston area
- Usual calcium intake 600-1200 mg/d based on two 24-hour dietary recalls by phone
Key exclusion criteria (3 listed)
- History of any chronic illness.
- Regularly taken (daily) medications (except seasonal allergies).
- Avoidance of dairy products or meat in the diet.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Vitamin DSubjects will be provided supplemental vitamin D3 (1000 IU) or placebo, given once daily (based on the stratification noted above). Vitamin D/placebo will be provided using a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks. | Dietary supplement | Placebo, Vitamin D |
Primary outcome
To evaluate the effects of supplemental vitamin D in enhancing calcium absorption in healthy children 4 to 8 yrs of age.
Time frame: End of the study
1 secondary outcome
Assess the absorption of magnesium and zinc in healthy children 4 to 8 yrs of age.
Time frame: End of the study
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Nov 2011.
- Background: PubMed 16087995Abrams SA, Griffin IJ, Hawthorne KM, Liang L, Gunn SK, Darlington G, Ellis KJ. A combination of prebiotic short- and long-chain inulin-type fructans enhances calcium absorption and bone mineralization in young adolescents. Am J Clin Nutr. 2005 Aug;82(2):471-6. doi: 10.1093/ajcn.82.2.471.
- Background: PubMed 17884999Abrams SA, Hawthorne KM, Aliu O, Hicks PD, Chen Z, Griffin IJ. An inulin-type fructan enhances calcium absorption primarily via an effect on colonic absorption in humans. J Nutr. 2007 Oct;137(10):2208-12. doi: 10.1093/jn/137.10.2208.
- Background: PubMed 10393137Ames SK, Gorham BM, Abrams SA. Effects of high compared with low calcium intake on calcium absorption and incorporation of iron by red blood cells in small children. Am J Clin Nutr. 1999 Jul;70(1):44-8. doi: 10.1093/ajcn/70.1.44.
- Background: PubMed 9063021Beard JL, Dawson H, Pinero DJ. Iron metabolism: a comprehensive review. Nutr Rev. 1996 Oct;54(10):295-317. doi: 10.1111/j.1753-4887.1996.tb03794.x.
- Background: PubMed 15093761Bischoff-Ferrari HA, Dietrich T, Orav EJ, Dawson-Hughes B. Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med. 2004 May 1;116(9):634-9. doi: 10.1016/j.amjmed.2003.12.029. No abstract available.
- Background: PubMed 18156197Bray MS, Shaw CA, Moore MW, Garcia RA, Zanquetta MM, Durgan DJ, Jeong WJ, Tsai JY, Bugger H, Zhang D, Rohrwasser A, Rennison JH, Dyck JR, Litwin SE, Hardin PE, Chow CW, Chandler MP, Abel ED, Young ME. Disruption of the circadian clock within the cardiomyocyte influences myocardial contractile function, metabolism, and gene expression. Am J Physiol Heart Circ Physiol. 2008 Feb;294(2):H1036-47. doi: 10.1152/ajpheart.01291.2007. Epub 2007 Dec 21.
- Background: PubMed 11177201Davidsson L, Ziegler EE, Kastenmayer P, Hurrell RF. Erythrocyte incorporation of iron by infants: iron bioavailability from a low-iron infant formula and an evaluation of the usefulness of correcting erythrocyte incorporation values, using a reference dose or plasma ferritin concentrations. Br J Nutr. 2000 Dec;84(6):847-53.
- Background: PubMed 15448662Donovan A, Andrews NC. The molecular regulation of iron metabolism. Hematol J. 2004;5(5):373-80. doi: 10.1038/sj.thj.6200540.
- Background: PubMed 10940348Eisenstein RS. Iron regulatory proteins and the molecular control of mammalian iron metabolism. Annu Rev Nutr. 2000;20:627-62. doi: 10.1146/annurev.nutr.20.1.627.
- Background: PubMed 12181175Fleet JC, Eksir F, Hance KW, Wood RJ. Vitamin D-inducible calcium transport and gene expression in three Caco-2 cell lines. Am J Physiol Gastrointest Liver Physiol. 2002 Sep;283(3):G618-25. doi: 10.1152/ajpgi.00269.2001.
- Background: PubMed 10198340Fleet JC, Wood RJ. Specific 1,25(OH)2D3-mediated regulation of transcellular calcium transport in Caco-2 cells. Am J Physiol. 1999 Apr;276(4):G958-64. doi: 10.1152/ajpgi.1999.276.4.G958.
- Background: PubMed 15341712Friend DR. Drug delivery to the small intestine. Curr Gastroenterol Rep. 2004 Oct;6(5):371-6. doi: 10.1007/s11894-004-0052-z.
Related trials for Mineral Absorption
Active, not recruiting
Vitamin and Mineral Absorption From Milk and PBMAs
Nutrition, Healthy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Steve Abrams, MD principal investigator
Baylor College of Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Vitamin D in people with Mineral Absorption, run by Baylor College of Medicine at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Nov 2011. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To evaluate the effects of supplemental vitamin D in enhancing calcium absorption in healthy children 4 to 8 yrs of age. (time frame: End of the study). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00868738, which also lists 36 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Nov 2011.